Xiao-Li Zhu

Xiao-Li Zhu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
HZHai-Dong Zhu
Hai-Dong Zhu
HLHai-Liang Li
Hai-Liang Li
MHMing-Sheng Huang
Ming-Sheng Huang
WYWei-Zhu Yang
Wei-Zhu Yang
GYGuo-Wen Yin
Guo-Wen Yin
GTGao-Jun Teng
Gao-Jun Teng
There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations. In this nationwide, retrospective, cohort study, 826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT (combination group, n = 376) or TACE monotherapy (monotherapy group, n = 450) were included from January 2018 to May 2021. The primary endpoint was progression-free survival (PFS) according to modified RECIST. The secondary outcomes included overall survival (OS), objective response rate (ORR), and safety. We performed propensity score matching approaches to reduce bias between two groups. After matching, 228 pairs were included with a predominantly advanced disease population. Median PFS in combination group was 9.5 months (95% confidence interval [CI], 8.4–11.0) versus 8.0 months (95% CI, 6.6–9.5) (adjusted hazard ratio [HR], 0.70, P = 0.002). OS and ORR were also significantly higher in combination group (median OS, 19.2 [16.1–27.3] vs. 15.7 months [13.0–20.2]; adjusted HR, 0.63, P = 0.001; ORR, 60.1% vs. 32.0%; P < 0.001). Grade 3/4 adverse events were observed at a rate of 15.8% and 7.5% in combination and monotherapy groups, respectively. Our results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS, OS, and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice, with an acceptable safety profile.

27 June 2023 in European Radiology
Verified
Journal Article
Open access
PDF file
ZJZhi-Cheng Jin
Zhi-Cheng Jin
BZBin-Yan Zhong
Bin-Yan Zhong
JCJian-Jian Chen
Jian-Jian Chen
HZHai-Dong Zhu
Hai-Dong Zhu
JSJun-Hui Sun
Jun-Hui Sun
FIfor the CHANCE Investigators
for the CHANCE Investigators
Objectives: This study aimed to investigate the efficacy and safety of transarterial chemoembolization (TACE) plus camrelizumab, a monoclonal antibody targeting programmed death-1, and apatinib for patients with intermediate and advanced hepatocellular carcinoma (HCC) in a real-world setting. Methods: A total of 586 HCC patients treated with either TACE plus camrelizumab and apatinib (combination group, n = 107) or TACE monotherapy (monotherapy group, n = 479) were included retrospectively. Propensity score matching analysis was used to match patients. The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety in the combination group were described in comparison to monotherapy. Results: After propensity score matching (1:2), 84 patients in the combination group were matched to 147 patients in the monotherapy group. The median age was 57 years and 71/84 (84.5%) patients were male in the combination group, while the median age was 57 years with 127/147 (86.4%) male in the monotherapy group. The median OS, PFS, and ORR in the combination group were significantly higher than those in the monotherapy group (median OS, 24.1 vs. 15.7 months, p = 0.008; median PFS, 13.5 vs. 7.7 months, p = 0.003; ORR, 59.5% [50/84] vs. 37.4% [55/147], p = 0.002). On multivariable Cox regression, combination therapy was associated with significantly better OS (adjusted hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.26–0.64; p < 0.001) and PFS (adjusted HR, 0.52; 95% CI, 0.37–0.74; p < 0.001). Grade 3 or 4 adverse events occurred in 14/84 (16.7%) and 12/147 (8.2%) in the combination and monotherapy groups, respectively. Conclusions: TACE plus camrelizumab and apatinib showed significantly better OS, PFS, and ORR versus TACE monotherapy for predominantly advanced HCC. Clinical relevance statement: Compared with TACE monotherapy, TACE plus immunotherapy and molecular targeted therapy showed better clinical efficacy for predominantly advanced HCC patients, with a higher incidence of adverse events. Key Points: • This propensity score–matched study demonstrates that TACE plus immunotherapy and molecular targeted therapy have a longer OS, PFS, and ORR compared with TACE monotherapy in HCC. • Grade 3 or 4 adverse events occurred in 14/84 (16.7%) patients treated with TACE plus immunotherapy and molecular targeted therapy compared with 12/147 (8.2%) patients in the monotherapy group, while no grade 5 adverse events were observed in all cohorts.

6 September 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
PDF file
BZBin-Yan Zhong
Bin-Yan Zhong
ZJZhi-Cheng Jin
Zhi-Cheng Jin
JCJian-Jian Chen
Jian-Jian Chen
HZHai-Dong Zhu
Hai-Dong Zhu
XZXiao-Li Zhu
Xiao-Li Zhu
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line recommendation for intermediate-stage HCC. In real-world clinical practice, TACE also plays an important role in early- and advanced-stage HCC. This review article by the experts from Chinese Liver Cancer Clinical Study Alliance (CHANCE) summarizes the available clinical evidence pertaining to the current application of TACE in patients with early-, intermediate-, and advanced-stage HCC. In addition, combination of TACE with other treatment modalities, especially immunotherapy, is reviewed.

18 February 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
FYFei Yang
Fei Yang
GXGui-Li Xu
Gui-Li Xu
JHJin-Tao Huang
Jin-Tao Huang
YYYu Yin
Yu Yin
WXWei Xiang
Wei Xiang
XZXiao-Li Zhu
Xiao-Li Zhu
Background: Locoregional therapy combined with systemic therapy can further improve the prognoses for HCC. However, the efficacy of TACE combined with ICIs and TKIs for HCC and whether this triple therapy can activate systemic immune response are still unknown.Purpose: To identify the efficacy of TACE+ICIs+TKIs for unresectable hepatocellular carcinoma (uHCC) and its effect on systemic immunity.Materials and Methods: This single-center retrospective study was approved by the Institutional Review Board. From August 1, 2019, to March 30, 2021, patients with uHCC who received the combination therapy of TACE+ICIs+TKIs were included. Peripheral blood samples were collected at baseline and once a month for 4 months after treatment. Lymphocyte subsets were measured by flow cytometry. Immunoglobulins were measured using the immune turbidimetric method. The dynamic change trend of circulating parameters was tested using simple linear regression.Results: Fifty-three patients with a mean age of 59 ± 10.6 years were included. TTP was 8.0 months (95% CI, 5.5–10.5) and PFS was 8.5 months (95% CI, 5.4–11.5). ORR was 52.8% and DCR was 81.1%. Twenty patients had completed analysis of biomarkers in peripheral blood. For cellular immune response, the level of circulating CD8+, CD3+ T cells and NK cells increased, the frequency of CD4+T cells and the CD4+/CD8+ ratio decreased, and among them, CD8+ T cells increased significantly. For humoral immune response, there was a significant decrease in B cells and a significant increase in Ig G, Ig κ, and Ig λ. Moreover, Ig G, Ig κ, and Ig λ were related to tumor response.Conclusion: TACE+ICIs+TKIs showed considerable efficacy in patients with uHCC. This triple therapy activated not only cell immune but also humoral immune activation. Circulating Ig G, Ig λ, and Ig κ can serve as potential biomarkers.

19 October 2022 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
FCFang‐Ming Chen
Fang‐Ming Chen
MDMingzhan Du
Mingzhan Du
XQXiumin Qi
Xiumin Qi
LBLinjie Bian
Linjie Bian
DWDanping Wu
Danping Wu
XZXiao-Li Zhu
Xiao-Li Zhu

7 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJiakun Guo
Jiakun Guo
JHJintao Huang
Jintao Huang
ZHZuliang Huang
Zuliang Huang
DHDi Hu
Di Hu
HTHujing Tan
Hujing Tan
ZZZhiyuan Zhong
Zhiyuan Zhong
Transarterial chemoembolization (TACE) is a common clinical intervention used for unresectable liver tumors, but conventional embolic microspheres generally exhibit slack vascular stacking and suboptimal drug release. Here, we report tumor vessel-adaptable, adhesive, and absorbable microspheres (3Asphere) based on hyaluronic acid developed using microfluidic and radical polymerization techniques for sustained TACE therapy of liver tumors. 3Asphere presents uniform sizes, gradual degradation over two months, and fast encapsulation and sustained release of chemotherapeutics such as epirubicin, irinotecan, and cisplatin. Interestingly, 3Asphere with high elasticity enables robust vascular embolization, effectively blocking rabbit renal blood supply for over one month. In rabbit VX2 orthotopic liver tumors, 3Asphere actively binds to endothelial cells via CD44 and inhibits tumor growth, affording significant survival benefits compared to commercial Embosphere®. TACE with epirubicin-loaded 3Asphere further enhances tumor inhibition and prevents lung metastasis. 3Asphere provides a versatile and advanced TACE therapy that might alleviate liver tumors.